Safety Considerations and Practical Strategies for Using Bispecific Antibodies in Multiple Myeloma

EP: 1.Unmet Needs and Emerging Therapeutic Advances in Multiple Myeloma

EP: 2.Challenges in the Management of Relapsed/Refractory Multiple Myeloma

EP: 3.Addressing Therapeutic Gaps in Multiple Myeloma with Bispecific Antibody Therapies

EP: 4.Bispecific Antibodies in Multiple Myeloma and Practical Definitions of Lines of Therapy

EP: 5.Mechanisms of Action of Bispecific Antibodies in Multiple Myeloma

EP: 6.Evaluating Clinical Trial Data and Real-World Evidence of Bispecific Antibodies in Multiple Myeloma

EP: 7.Bispecific Antibody Efficacy and Safety in Multiple Myeloma: Updates from ASH 2025

EP: 8.Clinical Insights on the Efficacy and Safety of Bispecific Antibodies in Multiple Myeloma

EP: 9.Exploring Combination Bispecific Strategies in Multiple Myeloma with Talquetamab and Teclistamab from RedirecTT-1 Trial

EP: 10.Opportunities for Earlier Initiation of Bispecific Therapies in Multiple Myeloma

EP: 11.Role of Antibody-Drug Conjugates in Multiple Myeloma

Now Viewing

EP: 12.Safety Considerations and Practical Strategies for Using Bispecific Antibodies in Multiple Myeloma

In this episode, experts outline key safety considerations and practical workflows for administering bispecific antibodies in clinical practice. Panelists emphasize that cytokine release syndrome and neurotoxicity associated with bispecific therapies are generally less severe than what is seen with CAR T cells. They stress the importance of educating clinicians and caregivers so that common symptoms, such as fever, are managed promptly using established pathways similar to those used for sepsis or febrile neutropenia. Infection risk is described as a major ongoing concern, with experts highlighting the need for early IVIG use and coordinated handoffs between academic centers and community practices to avoid gaps in monitoring. They also discuss the challenges community clinics face when initiating bispecific therapy, noting that once patients complete step-up dosing, toxicity risk decreases significantly, making transition of care more feasible. Overall, the discussion focuses on building systems that support safe, widespread use of these therapies.